

DOCKET NO.: CP380G
Application No.: 10/789,604
Office Action Dated: June 23, 2006

PATENT

RECEIVED
CENTRAL FAX CENTER
SEP 15 2008

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (currently amended) A method of treating colon, ovarian, renal, bladder, or prostate cancer in a human, which comprises administering to the human a combination of (i) a therapeutically effective amount of ~~one or more arsenic compounds~~ arsenic trioxide, and (ii) radiation.
2. (canceled)
3. (currently amended) The method of ~~claim 2~~ claim 1, wherein the arsenic trioxide is formulated as an ionic aqueous solution.
4. (currently amended) The method of claim 1, wherein the total daily amount administered of the arsenic ~~compound~~ arsenic trioxide is from about 10 µg to about 200 mg.
5. (currently amended) The method of claim 1, wherein the total daily amount administered of the arsenic ~~compound~~ arsenic trioxide is from about 0.5 mg to about 150 mg.
6. (currently amended) The method of claim 1, wherein the total daily amount administered of the arsenic ~~compound~~ arsenic trioxide is from about 0.5 mg to about 70 mg.
7. (currently amended) The method of claim 1, wherein the arsenic ~~compound~~ arsenic trioxide is administered parenterally.
8. (currently amended) The method of claim 1, wherein the arsenic ~~compound~~ arsenic trioxide is administered intravenously.
9. (currently amended) The method of claim 1, wherein the radiation and the arsenic ~~compound~~ arsenic trioxide are administered in combination with an effective amount of at least one further therapeutic agent.

DOCKET NO.: CP380G
Application No.: 10/789,604
Office Action Dated: June 23, 2006

PATENT

10. (original) The method of claim 9, wherein the further therapeutic agent is a chemotherapeutic or radiotherapeutic.

11. (original) The method of claim 9, wherein the further therapeutic agent is selected from the group consisting of etoposide, cisplatin, carboplatin, estramustine phosphate, vinblastine, methotrexate, hydroxyurea, cyclophosphamide, doxorubicin, 5-fluorouracil, taxol, diethylstilbestrol, VM-26(vumon), BCNU, all-trans retinoic acid, procarbazine, cytokines, therapeutic vaccines, and immunomodulators.

12. (currently amended) The method of claim 2 claim 1, wherein the dose of the arsenic trioxide is varied according to the body weight of the human.

13-15. (canceled)

16. (currently amended) The method of claim 2 claim 1, wherein the radiation is administered prior to the arsenic trioxide.

17. (currently amended) The method of claim 2 claim 1, wherein the radiation is administered after the arsenic trioxide.

18. (currently amended) The method of claim 2 claim 1, wherein the radiation and the arsenic trioxide are administered concurrently.